The news sent the company’s stock to its lowest level since March 2009. NeurogesX hasn’t reported a profit since the company began selling shares in 2007, and the stock has fallen 83 percent in the past year.
Advisors are scheduled to meet with regulators tomorrow, and a final decision is expected by March 7.
Related Articles on Pain Management:
Study: Spinal Cord Stimulation Effective for HIV Neuropathy
Pain Center of Arizona Opens New Clinic in Phoenix
Pain Physicians: What is the Biggest Factor Contributing to Your Practice’s Profitability?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
